Halozyme slips as German court overturns injunction against Merck
4 Articles
4 Articles
Merck (MSD) of the United States has seen its patent burden surrounding the immunotherapy drug ‘Keytruda Curex’ significantly reduced. This follows a complete victory in the U.S. patent invalidation trial against Halozyme Therapeutics. Alteogen’s subcutaneous (SC) injection technology is applied to Keytruda Curex. On the 18th (local time), the Patent Trial and Appeal Board (PTAB) under the U.S. Patent and Trademark Office (USPTO) [announced] tha…
German Court Overturns Keytruda SC Sales Ban, Opening Door to European Expansion
Keytruda Qlex, the subcutaneous formulation of Merck’s cancer immunotherapy drug Keytruda, which uses Alteogen’s ALT-B4 technology. The path to market entry in Germany, Europe’s largest pharmaceutical market, has opened for Keytruda SC, the subcutaneous formulation of the immuno-oncology drug developed by U.S.-based Merck (MSD), after a court overturned a preliminary injunction banning its sale. With both a German appellate court and the U.S. Th…
占싱깍옙 占쏙옙크(MSD)占쏙옙 kit占쏙옙占 占쏙옙占쏙옙怜占(SC) 占쏙옙占쏙옙占 占싸곤옙 占쌀뤄옙占쌈곤옙 占쏙옙占싱담옙 특占쏙옙 占쏙옙占∽옙占 占싱깍옙占쏙옙 占쏙옙占싹울옙占쏙옙 占쏙옙占싱억옙 占싱곤옙占.占싱깍옙占쏙옙占쏙옙占쏙옙 占쌀뤄옙占쏙옙 특占썬가 占쏙옙占쏙옙占쏙옙占 占쏙옙효 占실담옙占 占쌨았곤옙 占쏙옙占싹울옙占쏙옙占쏙옙 占실매몌옙 占쏙옙占쏙옙 占쏙옙占쏙옙 占쏙옙...
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium







